These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 28458135)
1. Inhibitors of cytochrome P450 (CYP) 1B1. Dutour R; Poirier D Eur J Med Chem; 2017 Jul; 135():296-306. PubMed ID: 28458135 [TBL] [Abstract][Full Text] [Related]
2. Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives. Poirier D; Roy J; Cortés-Benítez F; Dutour R Bioorg Med Chem Lett; 2016 Nov; 26(21):5272-5276. PubMed ID: 27687674 [TBL] [Abstract][Full Text] [Related]
3. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1. Lee D; Perez P; Jackson W; Chin T; Galbreath M; Fronczek FR; Isovitsch R; Iimoto DS Bioorg Med Chem Lett; 2016 Jul; 26(14):3243-3247. PubMed ID: 27265259 [TBL] [Abstract][Full Text] [Related]
4. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity. Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063 [TBL] [Abstract][Full Text] [Related]
5. Diaryl triazenes inhibit cytochrome P450 1A1 and 1B1 more strongly than aryl morpholino triazenes. Moran R; Nakamura R; Isovitsch R; Iimoto D Bioorg Med Chem Lett; 2022 Mar; 59():128570. PubMed ID: 35063631 [TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Chang YP; Huang CC; Shen CC; Tsai KC; Ueng YF Drug Metab Pharmacokinet; 2015 Oct; 30(5):374-83. PubMed ID: 26403084 [TBL] [Abstract][Full Text] [Related]
7. The Activation of Procarcinogens by CYP1A1/1B1 and Related Chemo-Preventive Agents: A Review. Li Y; Cui J; Jia J Curr Cancer Drug Targets; 2021; 21(1):21-54. PubMed ID: 33023449 [TBL] [Abstract][Full Text] [Related]
8. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Chun YJ; Oh YK; Kim BJ; Kim D; Kim SS; Choi HK; Kim MY Toxicol Lett; 2009 Aug; 189(1):84-9. PubMed ID: 19463925 [TBL] [Abstract][Full Text] [Related]
9. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors. Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055 [TBL] [Abstract][Full Text] [Related]
10. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance. Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. Shimada T; Guengerich FP Chem Res Toxicol; 2006 Feb; 19(2):288-94. PubMed ID: 16485905 [TBL] [Abstract][Full Text] [Related]
12. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells. Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study. Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993 [TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Hanna IH; Dawling S; Roodi N; Guengerich FP; Parl FF Cancer Res; 2000 Jul; 60(13):3440-4. PubMed ID: 10910054 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors. Dong J; Wang Z; Cui J; Meng Q; Li S Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634 [TBL] [Abstract][Full Text] [Related]
17. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship. Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300 [TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression. Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264 [TBL] [Abstract][Full Text] [Related]
19. Potential role of CYP1B1 in the development and treatment of metabolic diseases. Li F; Zhu W; Gonzalez FJ Pharmacol Ther; 2017 Oct; 178():18-30. PubMed ID: 28322972 [TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators. Chen D; Fan Q; Xu T; Dong J; Cui J; Wang Z; Wang J; Meng Q; Li S Anticancer Agents Med Chem; 2022; 22(2):261-269. PubMed ID: 33820523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]